Layton Mark E
Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., PO Box 4, West Point, PA 19486 USA.
Curr Top Med Chem. 2005;5(9):859-67. doi: 10.2174/1568026054750245.
This article describes recent advances in the development of subtype-selective, noncompetitive modulators of metabotropic glutamate receptor subtype 1 (mGluR1). mGluR1 plays an important role in modulating synaptic transmission and neuronal excitability via intracellular signal transduction pathways and has been implicated in a number of CNS disorders. Allosteric modulation of mGluR1 by potentiation and antagonism occurs through binding to the seven transmembrane domain. In addition to blocking agonist-dependent responses, many of the antagonists also show inverse-agonist activity by blocking constitutive receptor activity. Highly potent and selective mGluR1 radioligands have been used to evaluate receptor binding in vivo and in vitro. Some of these novel agents have demonstrated high levels of CNS exposure and receptor occupancy in vivo, as well as efficacy in a number of preclinical models of neurological disorders.
本文描述了代谢型谷氨酸受体1(mGluR1)亚型选择性、非竞争性调节剂开发方面的最新进展。mGluR1通过细胞内信号转导途径在调节突触传递和神经元兴奋性中发挥重要作用,并与多种中枢神经系统疾病有关。通过与七跨膜结构域结合,可对mGluR1进行变构增强和拮抗调节。除了阻断激动剂依赖性反应外,许多拮抗剂还通过阻断组成型受体活性表现出反向激动剂活性。高效且选择性的mGluR1放射性配体已用于体内和体外评估受体结合情况。其中一些新型药物在体内已显示出高脑内暴露水平和受体占有率,以及在多种神经疾病临床前模型中的疗效。